Furthermore, the researchers are looking at the potential for DT-109 to assist those suffering from inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis. Since these conditions are fundamentally characterized by a breakdown of the intestinal barrier and chronic gut inflammation, the protective effects of DT-109 could provide a new avenue for treatment where current therapies often fall short.
A Promising Treatment That Still Needs Human Trials
Despite the optimism surrounding these findings, the researchers emphasize that DT-109 is still in the experimental phase. While the data from animal and primate studies are robust, the transition from laboratory success to a pharmacy shelf is a long and careful process.
The next critical step involves moving the compound into human clinical trials. These trials will be necessary to determine the safety of DT-109 in humans, the appropriate dosages, and whether the dramatic reversal of MASH seen in primates will hold true for human patients with varying degrees of the disease.
"This study presents novel evidence about the pathogenesis of MASH and provides excitement about a therapeutic avenue to explore for a condition that remains difficult to treat," said Elliot Tapper, M.D., Academic Director of Hepatology at Michigan Medicine. "What patients with MASH need is a safe and effective therapy capable of improving their liver and heart health—of course we are excited about these developments."
The discovery marks a pivotal shift in the scientific understanding of fatty liver disease. For decades, the focus has been almost entirely on the liver’s internal metabolic processes. By looking outward to the gut and recognizing the liver as a victim of external microbial influences, Michigan Medicine researchers may have found the key to stopping the disease before it ever takes hold of the organ.
Funding and Institutional Disclosures
The development and study of DT-109 involve several institutional and financial partnerships. Ying Zhao, Oren Rom, Jifeng Zhang, and Y. Eugene Chen are listed as inventors on a patent application regarding the use of tripeptides for the treatment of metabolic, cardiovascular, and inflammatory disorders.
Dr. Chen is an inventor of DT-109, and the University of Michigan holds the patent for the compound. The technology has been licensed to Diapin Therapeutics, a company in which both Dr. Chen and the University of Michigan hold an ownership interest. Diapin Therapeutics supplied the DT-109 used in the research and is continuing the compound’s development.
The research was conducted under strict ethical guidelines. The human study protocols, amendments, and informed consent forms were approved by Institutional Review Boards at multiple participating sites, including the First Affiliated Hospital of Xi’an Jiaotong University, Jinan University, and the University of Hong Kong/Hospital Authority Hong Kong West Cluster.
All experimental procedures involving nonhuman primates were overseen and approved by the Laboratory Animal Care Committee of Xi’an Jiaotong University and the Institutional Animal Care and Use Committee of Spring Biological Technology Development Co., Ltd. The studies were conducted in full accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
